PMID- 37833657
OWN - NLM
STAT- MEDLINE
DCOM- 20231101
LR  - 20231121
IS  - 1471-2466 (Electronic)
IS  - 1471-2466 (Linking)
VI  - 23
IP  - 1
DP  - 2023 Oct 13
TI  - Effectiveness and safety of omalizumab in patients with allergic bronchopulmonary 
      aspergillosis with or without allergic rhinitis: a retrospective chart review.
PG  - 389
LID - 10.1186/s12890-023-02696-x [doi]
LID - 389
AB  - BACKGROUND: Omalizumab is a valuable alternative treatment for allergic 
      bronchopulmonary aspergillosis (ABPA). The effectiveness and safety of this 
      medication have not been confirmed. The main purpose of this study was to 
      evaluate the effectiveness and safety of omalizumab for ABPA. METHODS: This study 
      involved a retrospective chart review. The main indicators used were asthma 
      control test (ACT) scores, lung function parameters, doses of corticosteroids, 
      acute exacerbation, hospitalization rates, total serum immunoglobulin E (IgE) 
      levels, and blood eosinophil counts. Related adverse events were also reviewed to 
      evaluate the safety of omalizumab. RESULTS: Fourteen patients with ABPA were 
      included, of whom 10 (71%) concurrently had allergic rhinitis (AR). There were 
      improvements in the mean percentages of the forced vital capacity, percentages of 
      the forced expiratory volume in 1 s, and ACT score after omalizumab 
      administration (p < 0.05, p < 0.01, and p < 0.01, respectively). After the 
      initiation of omalizumab administration, the median corticosteroid dose, acute 
      exacerbation rate, hospitalization rate, and mean blood eosinophil count 
      decreased when compared with the baseline values (p < 0.05, p < 0.05, p < 0.01, 
      and p < 0.05, respectively). A reduction in the total serum IgE level was 
      observed in patients with ABPA without AR compared with that in patients with AR 
      (p < 0.05). One patient reported a concurrent skin rash, which spontaneously 
      resolved without medication. CONCLUSION: It is safe and effective to prescribe 
      omalizumab to patients with ABPA, irrespective of whether they have AR. Dose 
      adjustment of omalizumab is safe after disease control. The total serum IgE level 
      might be a predictor of the effectiveness of omalizumab in patients without AR.
CI  - (c) 2023. BioMed Central Ltd., part of Springer Nature.
FAU - Cai, Cuihong
AU  - Cai C
AD  - Department of Respiratory and Critical Care Medicine, The First Affiliated 
      Hospital, Zhejiang University College of Medicine, Hangzhou, 310003, People's 
      Republic of China.
FAU - Qu, Jingjing
AU  - Qu J
AD  - Department of Respiratory and Critical Care Medicine, The First Affiliated 
      Hospital, Zhejiang University College of Medicine, Hangzhou, 310003, People's 
      Republic of China.
FAU - Zhou, Jianying
AU  - Zhou J
AD  - Department of Respiratory and Critical Care Medicine, The First Affiliated 
      Hospital, Zhejiang University College of Medicine, Hangzhou, 310003, People's 
      Republic of China. zjyhz@zju.edu.cn.
LA  - eng
GR  - 2019C03042/Zhejiang Key Research and Development Program/
PT  - Journal Article
DEP - 20231013
PL  - England
TA  - BMC Pulm Med
JT  - BMC pulmonary medicine
JID - 100968563
RN  - 2P471X1Z11 (Omalizumab)
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Adrenal Cortex Hormones)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Humans
MH  - Omalizumab/therapeutic use
MH  - *Anti-Allergic Agents/therapeutic use
MH  - *Aspergillosis, Allergic Bronchopulmonary/drug therapy
MH  - Retrospective Studies
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - *Rhinitis, Allergic/complications/drug therapy
MH  - Immunoglobulin E
PMC - PMC10571511
OTO - NOTNLM
OT  - Allergic bronchopulmonary aspergillosis
OT  - Allergic rhinitis
OT  - Omalizumab
OT  - Total serum IgE level
OT  - anti-IgE antibody
COIS- The authors declare that they have no competing interests.
EDAT- 2023/10/14 10:42
MHDA- 2023/11/01 12:43
PMCR- 2023/10/13
CRDT- 2023/10/13 23:54
PHST- 2023/05/07 00:00 [received]
PHST- 2023/10/04 00:00 [accepted]
PHST- 2023/11/01 12:43 [medline]
PHST- 2023/10/14 10:42 [pubmed]
PHST- 2023/10/13 23:54 [entrez]
PHST- 2023/10/13 00:00 [pmc-release]
AID - 10.1186/s12890-023-02696-x [pii]
AID - 2696 [pii]
AID - 10.1186/s12890-023-02696-x [doi]
PST - epublish
SO  - BMC Pulm Med. 2023 Oct 13;23(1):389. doi: 10.1186/s12890-023-02696-x.